🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes

Recruitingn/aAges 18 Years - anyAllHospices Civils de Lyon
NCT05805566 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

SARS-CoV2 pneumonia has been a global public health emergency since 2020. The prevalence of the disease is particularly high with more than 500 million cases worldwide (7.5 million in France) since the emergence of the virus. A substantial proportion of patients with SARS-Cov2 infection present persistent symptoms long after the acute infection. This is independent of the degree of severity of the SARS-Cov2 infection. These symptoms can affect the quality of life and impede the return to work. While the majority of symptoms progress favourably with outpatient care, some persist and/or are particularly severe, justifying expert and multidisciplinary care. This investigation aim to create a clinical database of patients with complex and/or severe post-CoviD and study blood markers what could predict the disease and orientate new ways of treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: All patients who have joined the Epsilon care pathway since its opening in February 2022, i.e.: * Patients with post-Covid syndrome referred to the Epsilon sector from the city medicine: * Patient with documented SARS-Cov2 pneumonia * With persistent and severe symptoms beyond 4 weeks or complex or disabling symptoms beyond 3 months * Patient over 18 years old. Post-hospital sector: * Patient with documented SARS-Cov2 pneumonia * Hospitalized for oxygen therapy (at least 48h) * Not having a referring pulmonologist * Not institutionalized * With a life expectancy of more than 6 months. Exclusion Criteria: * Patient refusing that this data to be used for research purposes (objection form). * Patient with untreated comorbidities
💊

What it tests

  • Blood collection
📍

Where

1 site
Department of Acute Pneumology and Thoracic Oncology, Hôpital Lyon Sud, Hospices Civils de Lyon
Pierre-Bénite, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy